Ga 68 PSMA-11

The phase 2 Co-PSMA trial will compare ⁶⁴Cu-SAR-bisPSMA with ⁶⁸Ga-PSMA-11 PET/CT in detecting prostate cancer recurrence in 50 patients. Led by Dr. Louise Emmett at St. Vincent’s Hospital, Sydney, the study aims to assess the detection rate of recurrence sites. ⁶⁴Cu-SAR-bisPSMA received FDA fast track designation in 2024, following favorable results from the PROPELLER trial, which led to the ongoing CLARIFY trial.

Clarity Pharmaceuticals advances prostate cancer diagnostics with Phase II trial at St Vincent’s Hospital, comparing 64Cu-SAR-bisPSMA against standard 68Ga-PSMA-11, aiming for superior cancer detection and treatment outcomes.

In a phase II trial (NCT04928820), 68Ga-PSMA-11 PET/CT and 99mTc-MDP planar bone scan plus CT showed identical bone metastasis detection rates in prostate cancer patients with biochemical progression during ADT. Both scans detected equal numbers of bone lesions in 64% of patients, with PSMA PET/CT detecting more in 27% and bone scan plus CT detecting more in 9.1%. Inter-reader agreement was higher for PSMA PET/CT (96%) than for bone scan plus CT (82%).

Health Canada approves Illuccix for selecting patients with progressive metastatic castration-resistant prostate cancer (mCRPC) for PSMA-targeted radionuclide therapy, expanding its clinical utility in Canada.

64Cu-SAR-bisPSMA received FDA fast track designation for PET imaging of PSMA-positive prostate cancer lesions. Clinical trials showed 100% and 85.7% detection rates, higher uptake than 68Ga-PSMA-11, and minimal adverse effects, positioning it as a potential best-in-class diagnostic.